The Ulspira Solution combines inhaled nitric oxide (iNO) gas with a portable delivery system and clinical support to treat infants with hypoxic respiratory failure.


RT’s Three Key Takeaways:

  1. Rapid Therapy Initiation: The delivery system features a quick pre-use check and automatic purging to allow clinicians to start nitric oxide treatment within minutes for vulnerable neonates.
  2. Enhanced Patient Safety: Critical safety elements include an emergency dosing mode, an integrated pneumatic backup for manual bagging, and continuous monitoring of gas concentrations.
  3. Streamlined Clinical Workflow: An optional service program handles routine tasks like device calibration and inventory management to reduce the administrative workload for respiratory therapy departments.


Airgas Therapeutics (an Air Liquide company) offers the Ulspira Solution, a system designed to provide inhaled nitric oxide (iNO) therapy for neonates. The solution is indicated for term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension in neonatal intensive care unit (NICU) and transport settings, according to Airgas.

The system includes Food and Drug Administration (FDA) approved ULSPIRA gas and the ULSPIRA TS delivery device. The device is designed for ease of use with a touchscreen interface, digital dosing, and integrated instructions to minimize user errors during emergencies.

“The Ulspira TS Nitric Oxide Therapy System is intended for use by healthcare professionals for the delivery of nitric oxide (NO) and the monitoring of inspired NO, NO2, and O2 concentrations,” the company says.

To facilitate rapid treatment, the system features a pre-use check that takes minutes and automatic purging. The device also includes an internal battery providing at least two hours of therapy and an integrated, pneumatic backup system for use during patient hand-bagging or power loss.

The solution also includes Ulspira Care+, a program of customizable services designed to reduce the workload for respiratory therapists and other healthcare professionals. This program provides onsite support for routine tasks, including device maintenance and high calibration.

The service model utilizes a patient-tracking system that provides data on treatment duration and usage by device. This model is intended to simplify hospital billing and eliminate the manual counting of cylinders and supplies by clinical staff.

“The Ulspira TS takes the guesswork out of therapy administration to reduce your burden of care in the NICU,” said the company in a product brochure.

The Ulspira TS is validated for a wide range of ventilation modes and features a detachable device head that can mount to a bedside cart or bedrail holder for use during transit. The system also includes a gas-supply calculator to help clinicians validate how long a cylinder will last based on ventilatory parameters and the set dose.

Source

  1. https://www.airgas.com/ulspira
  2. [PDF] https://www.airgas.com/medias/airgas-therapeutics-ulspira-solution-brochure-202407-print-M3-lowres.pdf